Follicular Lymphoma | Clinical

Rituximab Plus Anthracycline-Based Chemotherapy Prolongs Survival Long-Term in Follicular Lymphoma

January 08, 2021

Rituximab added to standard anthracycline-based chemotherapy demonstrated significant improvements in progression-free survival as well as overall survival as treatment of patients with follicular lymphoma, according to 35-year follow-up results of patients treated through the Nebraska Lymphoma Study Group.

Broad Spectrum of Upfront Therapies Available for Follicular Lymphoma

December 10, 2020

In an interview with Targeted Oncology, John M. Burke, MD, discussed the current treatment paradigm for patients with follicular lymphoma and reviewed the factors he considers when making treatment decisions for this population.

Mosunetuzumab Elicits High and Durable Responses in Subgroups of Patients With FL

December 08, 2020

A phase clinical trial has demonstrated that administering a mosunetuzumab fixed-duration leads to high, durable, and consistent responses in patients with follicular lymphoma across multiple subgroups. Data from the study were presented during the virtual 2020 American Society of Hematology Annual Meeting.

R-CHOP Found Superior in Grade 3A, 1-2-3A Follicular Lymphoma

November 13, 2020

A new retrospective analysis has suggested that the R-CHOP chemotherapy regimen of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone leads to superior outcomes compared to rituximab plus bendamustine in patients with grade 3A follicular lymphoma.

In Low-Grade Follicular Lymphoma, Expert Weighs Frontline Options

November 04, 2020

A general framework can be utilized to guide treatment decision in patients with follicular lymphoma, according to John P. Leonard, MD. During a presentation for the 38th Annual Chemotherapy Foundation Symposium, Leonard also explained that bulk of disease, comorbidities, and toxicity, among others are all factors that impact treatment decisions.

FDA to Review sBLA for Axi-Cel in R/R Follicular Lymphoma and Marginal Zone Lymphoma

September 05, 2020

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.

Doctors Debate: Should Asymptomatic Patients With Follicular Lymphoma Be Actively Monitored With Watch-and-Wait Strategy or Immediately Treated?

September 01, 2020

The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.